Principia Biopharma is dedicated to bringing transformative oral therapies to patients with significant unmet medical needs to improve patient outcomes and experience. Our proprietary Tailored Covalency® platform enables us to design and develop oral therapies that we believe will rival the effectiveness and safety of injectable biologics, yet maintain the convenience of a pill.
We are currently enrolling patients in the following clinical trials:
PEMPHIGUS (PEMPHIGUS VULGARIS AND PEMPHIGUS FOLIACEUS)
Phase 3 clinical trial with PRN1008 for pemphigus, an autoimmune blistering skin disorder that has limited options for treatment. Clinical trial information can be found here (https://clinicaltrials.gov/ct2/show/NCT03762265) and information related to the disease can be found here (http://www.pemphigus.org/).
Phase 2 clinical trial information can be found here (https://www.clinicaltrials.gov/ct2/show/NCT02704429)
Immune Thrombocytopenic Purpura
Phase 1/2 clinical trial with oral PRN1008 for Immune Thrombocytopenic Purpura (ITP), an autoimmune disease causing low platelet levels in the blood. Clinical trial information can be found here (https://clinicaltrials.gov/ct2/show/NCT03395210) and information related to the disease can be found here (https://pdsa.org/).
Solid Tumors (Including Bladder Cancer)
Phase 1 expansion and safety study with PRN1371, a selective, oral, FGFR 1-4 inhibitor in patients with solid tumors. Clinical trial information can be found here (https://www.clinicaltrials.gov/ct2/show/NCT02608125).
Please check back again for updates on future clinical trials.